Author(s): Rehan Haider


DOI: 10.52711/2231-5659.2023.00007   

Address: Rehan Haider
Riggs Pharmaceuticals Karachi, Department of Pharmacy, University of Karachi - Pakistan.
*Corresponding Author

Published In:   Volume - 13,      Issue - 1,     Year - 2023

Medicine are a core part of health-care services and their use has grown enormously during the last century with the advent of effective Antibiotics, Anesthetics, Analgesics, Anti-retroviral and many other medicines, they can cure diseases, relieve symptoms and prevent future ill health. Appropriate medicine use means providing the right medicine at the right dose, when it is needed and avoiding medicine that are unnecessary or are unlikely to result in health benefits it means choosing the treatment with the best effectiveness and safety profile among available alternatives and the least costly of equivalent treatments. The international pharmaceutical industry plays an important role in the development, production and distribution of medicines. In many countries it has also become the major funder of continuing medical education (CME) and research. However, a tension exists between pressure to expand products sales within a competitive market and patient care. The World Health Organization (WHO) describe" an inherent conflict of interest between the legitimate business goals of manufacturers and the social, medical and economic needs of providers and the public to select and use drugs in the most rational way"( WHO Europe 1993)1 The Global Medicine Market: In 2007, global pharmaceutical sales amounted to US $ 712 billion (IMS 2008)2 The top product in term of sales, was the cholesterol lowering medicine, Lipitor (Atorvastatin), which had sales of US $ 13.6 billion (scrip.2007)3. This is more than the gross national income of over half of the world’s countries (World Bank, 2008)4. The effects of promotion in fueling sales of specific brands should not be underestimated e.g. sales of Lipitor (Atorvastatin) were higher than sales of simvastatin and Provaststin, two medicine in the same class that have similar effectiveness and are less costly (Preserire, 2006) 5. Newer Medicine are not necessarily better: To get a new medicine to market, a company must provide evidence of effectiveness, safety and manufacturing quality. Effectiveness and safety evidence includes laboratory animal and clinical studies. The largest are phase III randomized controlled trials in patient with the disease the medicine aims to treat. Most of these studies compare a new medicine to a placebo. Many people are unaware that manufacturers do not need to show that a new medicine is better than existing compound with placebo and be acceptably safe. To test the medicine 's efficacy, the manufacturers carried out the randomized, controlled trials involving patients with the condition to be treated by the new medicine. These are usually relatively short-term studies and many last a few weeks to a few months, even when the treatment for a chronic disease. For some serious disease for which placebo treatment would be unethical, a new medicine is compared with existing treatments. However, these studies aim to show that a new medicine is as effective as alternatives, or no less effective, it does not need to be better, when a new medicine comes to the has only been tested on highly selected groups of clinical trials participants. e.g. the elderly and those with co-morbid, chronic conditions are usually excluded. To few people have been exposed to asses’ rare harmful effects, generally 3, 000 to 5, 000 peoples. Because of this inevitably incomplete safety assessment, there is a rational from a public health perspective and an individual patient Care perspective for a slow, cautious approach to the introduction of new medicines.

Cite this article:
Rehan Haider. Promotional Tools in Pharmaceutical Marketing. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(1):40-4. doi: 10.52711/2231-5659.2023.00007

Rehan Haider. Promotional Tools in Pharmaceutical Marketing. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(1):40-4. doi: 10.52711/2231-5659.2023.00007   Available on:

1.    World Health organization (1993) clinical pharmacological evaluation in drug control Copenhagen, world health organization. Regional office for Europe document reference EUR/ ICP/ DSE 173
2.    IMS Health market prognosis (2008) Global pharmaceutical sales 2000-2007, 28 March.http// w.w.w.ims portal/ site/ imps health/ menu item. a 46c 6d4d f3d b4b3d88f611019418c229/? Vgnextoid 6    7a89d f4609e911ovgn VCM10000071812 can2RCRDand cpsextcurrchannel -1, accessed 17 April2009.
3.    Scrap(2007) choixd ' une ' eprouvees quel' atorvestatin revue prescrire 26(276)692-695
4.    World Bank(2008)world development indicators 2007.Total Gross National Income (GNI), Atlas method DATASTATISTICS/Resources(GNI.pdf.accessed17April2009)
5.    Prescrire (2006) choice d ' unestatine : pravastatine et simvestatine sont mievx eprouvees quel' atorveastatine LA revue prescrire 26(276)692-695
6.    Prosper H Almond S.walley T(2003) influence on GPs decision to prescribe new drugs - the importance of who says what Family practice 20(1)61-68
7.    Zipkin DA, Steinman MA(2005) interaction between pharmaceutical representative and doctors in training a thematic review, Journal of General internal Medicine, June 13, 20(8) 777-86
8.    Brennan TA, RothmanDj, Blank L (2006) Health industry practice that create conflict of interest. A policy proposal for academic medical centers Journal of American Medical Association, 295:429-433
9.    Campbell EG, Gruen RL, Mountford J (2007) A national survey of physicians industry relationships New England Journal of Medicine356: 1742-1750
10.    WazanaA (2000) Physicians and the pharmaceutical industry, Is a gift ever just a gift ? Journal of the American Medical Association, 283: 373-380
11.    Gagnon MA, LexchinJ ( 2008) the cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the united states .Plos Med 5 (1): el
12.    Stein man2006 Narrative review the promotion of gabapentine an analysis of internal industry document Annals of internal medicine45: 284-293
13.    Hensley S, Martinez B (2005) new treatment : To sell their drugs, companies increasingly rely on doctors. For $ 750 and up physician tell peers about product. wall street journal (New York), 15 July, 2005 AL
14.    CaplovitzA (2006) Turning medicine into snake oil : pharmaceutical marketers put patient at risk. NJPIRG law and policy center, US( http, accessed 17 April 2009)
15.    Hensley S, Martinez B, (2005) New treatment : to sell their drugs, companies increasingly rely on doctors For $ 750 and up. Physicians tell peers about product wall street journal ( New York) 15 July 2005 Al
16.    Spurgeon D (2007) New York times reveals payment to doctors by drug firms. British Medical Journal334:655
17.    Steinbrook R(2005)commercial support and continuing medical education New England Journal of Medicine, 352: 534-535
18.    Boltri JM (2002) Effect of antihypertensive samples on physicians prescribing pattern family medicine journal 34: 729-731
19.    Arnold M (2005) All the talk about pharma ROI yields only diminishing returns Medical Marketing and Media 40(3) 9
20.    Fortune 500 (2007) Top industries: most profitable industries, return on investment, 30 April magazine/ Fortune/ Fortune 500/ 2007/ performers/ industries/ return_on_ revenues/ index.html, accessed 17April 2009
21.    Avorn (1982) scientific verses commercial sources of influence on the prescribing behavior of physicians American Journal of Medicine73: 4-9
22.    Adair RF (2005) do drugs samples influence resident prescribing behavior ? A randomized trials American Journal of medicine 118: 881-884
23.    Lidstone J, Collier T, ( 1987) Marketing planning for the pharmaceutical industry, Aldershot, UK Gower http// promotion / textbook/ market/ behavior.htm., accessed 17 April 2009
24.    Schafer A (2004) Biomedical conflict of interest : a defense of the sequestration thesis journal of Medical Ethics 2004: 30: 8-24 p 21
25.    Cialdini RB( 2000) influence .science and practice 4 th ed New York, Allyn and Bacon
26.    Steinman (2001) Of principles and pend attitude and practice of medicine house staff towards, industry documents. Annals of internal Medicine 45: 284-293
27.    Katz D, Caplan AL, Merz JF (2003) All gift large and small American journal of Bioethics, 3: 39- 46
28.    O ' Keefe DJ (2002) persuasion: theory and research 2nd Med thousand ca ks California sage publications.
29.    WHO(1988) World Health Organization Ethical criteria for medicinal drug promotion Geneva, WHO
30.    Mintzes B (2005) Educational initiative for medical and pharmacy student about drug promotion. An international cross - section survey World Health organization and Health Action International. Document reference WHO/ PSM/ PAR/ 2005.2

Recomonded Articles:

Author(s): Mohd. Yaqub Khan, Maryada Roy, Brijesh Kumar Saroj, Sudhakar Dubey, Vineet Kumar Sharma

DOI: 10.5958/2231-5659.2015.00019.3         Access: Open Access Read More

Author(s): Manukondakeerthi, Lakshmiprasanna. J, Santhosh aruna M, Rama Rao N

DOI:         Access: Open Access Read More

Author(s): Dibyajyoti Saha, Milan Hait, Mayukh Jana, Suprodip Mandal, Utpal Jana

DOI:         Access: Open Access Read More

Author(s): Namdeo Shinde, Nagesh Aloorkar, Ajit Kulkarni, Bhaskar Bangar, Suyog Sulake, Pratik Kumbhar

DOI:         Access: Open Access Read More

Author(s): Amol P. Suryawanshi, Dattatraya M. Shinkar, R.B. Saudagar.

DOI: 10.5958/0975-4377.2015.00013.0         Access: Open Access Read More

Author(s): Saudagar R. B., Sarika V. Khandbahale

DOI: 10.5958/2231-5659.2017.00005.4         Access: Open Access Read More

Author(s): Pradnya M. Khandagale, Bhushan Bhairav, R. B. Saudagar

DOI: 10.5958/2231-5659.2016.00038.2         Access: Open Access Read More

Author(s): Rajashri R. Kulkarni, Dipti G. Phadtare, Ravindra B. Saudagar

DOI: 10.5958/2231-5659.2016.00019.9         Access: Open Access Read More

Author(s): Pankaj R. Dhapake, Chauriya C.B., Umredkar R.C.

DOI: 10.5958/2231-5659.2017.00001.7         Access: Open Access Read More

Author(s): Vrushali R. Kadam, M. P. Patil, Vrushali V. Pawar, Sanjay Kshirsagar

DOI: 10.5958/2231-5659.2017.00030.3         Access: Open Access Read More

Author(s): S. S. Shuka, Bina Gidwani, R. Pandey, S. P. Rao, V. Singh, Amber Vyas

DOI:         Access: Open Access Read More

Author(s): Viral Patel

DOI:         Access: Open Access Read More

Author(s): Sana Banu, Syeda Ayesha Farheen

DOI: 10.5958/2231-5659.2019.00015.8         Access: Open Access Read More

Author(s): Darekar A. B. , Zope Janhavi S. , Saudagar R. B.

DOI: 10.5958/2231-5659.2016.00013.8         Access: Open Access Read More

Author(s): Kadam T.V. , Darekar A.B., Gondkar S.B., Saudagar R.B.

DOI: 10.5958/2231-5659.2015.00014.4         Access: Open Access Read More

Author(s): Sushil D. Patil, Prajkta Varpe, Sayali Chaure, Siddharth B. Bhalerao, Sanjay Kshirsagar

DOI: 10.5958/2231-5659.2017.00034.0         Access: Open Access Read More

Author(s): D.M. Shinkar, Bhushan S Bhamare, R.B. Saudagar

DOI: 10.5958/2231-5659.2016.00011.4         Access: Open Access Read More

Asian Journal of Research in Pharmaceutical Sciences (AJPSci) is an international, peer-reviewed journal, devoted to pharmaceutical sciences....... Read more >>>

RNI: Not Available                     
DOI: 10.52711/2231-5659 

Recent Articles